Xiaoxi Lv

2.3k total citations
43 papers, 1.7k citations indexed

About

Xiaoxi Lv is a scholar working on Epidemiology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xiaoxi Lv has authored 43 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Epidemiology, 16 papers in Molecular Biology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiaoxi Lv's work include Autophagy in Disease and Therapy (14 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (9 papers) and Endoplasmic Reticulum Stress and Disease (6 papers). Xiaoxi Lv is often cited by papers focused on Autophagy in Disease and Therapy (14 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (9 papers) and Endoplasmic Reticulum Stress and Disease (6 papers). Xiaoxi Lv collaborates with scholars based in China, United States and Canada. Xiaoxi Lv's co-authors include Fang Hua, Zhuowei Hu, Bing Cui, Jiaojiao Yu, Xiaowei Zhang, Shanshan Liu, Ke Li, Jinmei Yu, Shuang Shang and Bo Huang and has published in prestigious journals such as Circulation, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Xiaoxi Lv

42 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaoxi Lv China 23 897 408 351 298 296 43 1.7k
Wei Cui United States 22 939 1.0× 364 0.9× 164 0.5× 519 1.7× 356 1.2× 86 1.8k
Miguel Reina‐Campos United States 21 1.2k 1.4× 395 1.0× 272 0.8× 628 2.1× 672 2.3× 24 2.3k
Stephan Singer Germany 28 1.2k 1.3× 279 0.7× 201 0.6× 458 1.5× 468 1.6× 76 2.1k
Jianghua Shao China 22 838 0.9× 228 0.6× 186 0.5× 453 1.5× 441 1.5× 51 1.4k
Guang‐Zhi Jin China 25 1.2k 1.3× 200 0.5× 228 0.6× 380 1.3× 733 2.5× 48 1.7k
Yaojie Fu United States 21 678 0.8× 469 1.1× 186 0.5× 372 1.2× 436 1.5× 31 1.5k
Min‐Bin Chen China 30 1.5k 1.6× 334 0.8× 293 0.8× 697 2.3× 624 2.1× 83 2.4k
Femke Heindryckx Sweden 22 625 0.7× 695 1.7× 152 0.4× 284 1.0× 359 1.2× 45 1.8k
Yuezhen Deng China 20 1.1k 1.3× 189 0.5× 130 0.4× 421 1.4× 646 2.2× 34 1.8k

Countries citing papers authored by Xiaoxi Lv

Since Specialization
Citations

This map shows the geographic impact of Xiaoxi Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoxi Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoxi Lv more than expected).

Fields of papers citing papers by Xiaoxi Lv

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoxi Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoxi Lv. The network helps show where Xiaoxi Lv may publish in the future.

Co-authorship network of co-authors of Xiaoxi Lv

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoxi Lv. A scholar is included among the top collaborators of Xiaoxi Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoxi Lv. Xiaoxi Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Jiaojiao, Yuzhen Gao, Shan Chang, et al.. (2024). PKCα inhibitors promote breast cancer immune evasion by maintaining PD-L1 stability. Acta Pharmaceutica Sinica B. 14(10). 4378–4395. 6 indexed citations
2.
Liu, Chang, Yuxin Liu, Yi Liu, et al.. (2023). Network Pharmacology, Molecular Docking and Experimental VerificationRevealing the Mechanism of Fule Cream against Childhood AtopicDermatitis. Current Computer - Aided Drug Design. 20(6). 860–875.
3.
Lv, Xiaoxi, Shanshan Liu, Chang Liu, et al.. (2023). TRIB3 promotes pulmonary fibrosis through inhibiting SLUG degradation by physically interacting with MDM2. Acta Pharmaceutica Sinica B. 13(4). 1631–1647. 13 indexed citations
4.
5.
Zhou, Ji‐Chao, Ruoyu Wang, Zhimeng Zhang, et al.. (2023). Mesaconine alleviates doxorubicin-triggered cardiotoxicity and heart failure by activating PINK1-dependent cardiac mitophagy. Frontiers in Pharmacology. 14. 1118017–1118017. 23 indexed citations
6.
Shang, Shuang, Liang Yu, Ke Li, et al.. (2022). TRIB3 reduces CD8 + T cell infiltration and induces immune evasion by repressing the STAT1-CXCL10 axis in colorectal cancer. Science Translational Medicine. 14(626). eabf0992–eabf0992. 100 indexed citations
7.
Fu, Rong, Jun Tai, Xia Yuan, et al.. (2022). S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung. Acta Pharmaceutica Sinica B. 13(3). 1110–1127. 7 indexed citations
8.
Lv, Xiaoxi, Chang Liu, Shanshan Liu, et al.. (2021). The cell cycle inhibitor P21 promotes the development of pulmonary fibrosis by suppressing lung alveolar regeneration. Acta Pharmaceutica Sinica B. 12(2). 735–746. 32 indexed citations
9.
Liu, Shanshan, Xiaoxi Lv, Chang Liu, et al.. (2021). TRIB3‒GSK-3β interaction promotes lung fibrosis and serves as a potential therapeutic target. Acta Pharmaceutica Sinica B. 11(10). 3105–3119. 27 indexed citations
10.
Liu, Shanshan, Chang Liu, Xiaoxi Lv, et al.. (2021). The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis. Immunity. 54(9). 2042–2056.e8. 90 indexed citations
11.
Yu, Jiaojiao, Dandan Zhou, Bing Cui, et al.. (2020). Disruption of the EGFR-SQSTM1 interaction by a stapled peptide suppresses lung cancer via activating autophagy and inhibiting EGFR signaling. Cancer Letters. 474. 23–35. 15 indexed citations
12.
Yu, Jinmei, Wei Sun, Zhenhe Wang, et al.. (2019). TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription. Nature Communications. 10(1). 5720–5720. 162 indexed citations
13.
Li, Ke, Tingting Zhang, Feng Wang, et al.. (2018). Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression. Oncogene. 37(22). 2967–2981. 47 indexed citations
14.
15.
Lv, Xiaoxi, Shanshan Liu, & Zhuowei Hu. (2017). Autophagy-inducing natural compounds: a treasure resource for developing therapeutics against tissue fibrosis. Journal of Asian Natural Products Research. 19(2). 101–108. 16 indexed citations
16.
Li, Ke, Feng Wang, Wenbin Cao, et al.. (2017). TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence. Cancer Cell. 31(5). 697–710.e7. 94 indexed citations
17.
Yan, Huimin, Bing Cui, Xiaowei Zhang, et al.. (2015). Antagonism of toll-like receptor 2 attenuates the formation and progression of abdominal aortic aneurysm. Acta Pharmaceutica Sinica B. 5(3). 176–187. 23 indexed citations
18.
Wang, Ziyan, Jun Yan, Heng Lin, et al.. (2013). Toll-like receptor 4 activity protects against hepatocellular tumorigenesis and progression by regulating expression of DNA repair protein Ku70 in mice. Hepatology. 57(5). 1869–1881. 49 indexed citations
19.
Wang, Xiaoxing, Xiaoxi Lv, Huimin Yan, et al.. (2013). Blocking TLR2 activity diminishes and stabilizes advanced atherosclerotic lesions in apolipoprotein E-deficient mice. Acta Pharmacologica Sinica. 34(8). 1025–1035. 18 indexed citations
20.
Lv, Qi, Wei Wang, Jianfei Xue, et al.. (2012). DEDD Interacts with PI3KC3 to Activate Autophagy and Attenuate Epithelial–Mesenchymal Transition in Human Breast Cancer. Cancer Research. 72(13). 3238–3250. 141 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wei Cui Breakdown of academic impact, for papers by Miguel Reina‐Campos Breakdown of academic impact, for papers by Stephan Singer Breakdown of academic impact, for papers by Jianghua Shao Breakdown of academic impact, for papers by Guang‐Zhi Jin Breakdown of academic impact, for papers by Yaojie Fu Breakdown of academic impact, for papers by Min‐Bin Chen Breakdown of academic impact, for papers by Femke Heindryckx Breakdown of academic impact, for papers by Yuezhen Deng
Rankless by CCL
2026